B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target
Portfolio Pulse from richadhand@benzinga.com
B of A Securities analyst Geoff Meacham has reinstated Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy rating and announced a $14 price target.
July 20, 2023 | 10:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acumen Pharmaceuticals has been reinstated with a Buy rating by B of A Securities, with a price target of $14.
The reinstatement of the Buy rating and the setting of a $14 price target by B of A Securities is a positive signal for Acumen Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100